Atezolizumab Approved for Stage III dMMR Colon Cancer

The approval and who it covers

The approval applies to adults and pediatric patients aged 12 years and older who have stage III colon cancer with deficient mismatch repair, commonly abbreviated dMMR, following surgical resection. It does not cover children younger than 12 years, stage I or II disease, rectal cancer, unresectable disease, or metastatic colon cancer under this specific adjuvant indication.

Stage III means that the cancer has spread to regional lymph nodes but not to distant organs. The treatment is adjuvant: it is given after surgery with curative intent to reduce the risk of recurrence from clinically undetectable residual disease. Atezolizumab is a programmed death-ligand 1, or PD-L1, inhibitor; the approved strategy combines it with fluoropyrimidine-, leucovorin- and oxaliplatin-based chemotherapy rather than replacing postoperative chemotherapy.

Biomarker status is central to eligibility. dMMR tumors have lost normal activity in one or more mismatch-repair proteins, impairing correction of DNA replication errors and generally producing a high mutational burden. In routine pathology, dMMR is commonly identified by immunohistochemistry showing loss of MLH1, MSH2, MSH6 or PMS2 expression. Molecular testing for microsatellite instability may provide related information, but clinicians should verify that the reported result satisfies the biomarker requirement in the FDA-approved labeling.

The indication is therefore narrower than “stage III colon cancer.” A patient must meet the anatomic, postoperative, age and biomarker criteria. Conversely, the approval is not restricted to a particular nodal subgroup within stage III disease, sex or adult age bracket unless another label provision applies.

Evidence supporting the decision

The regulatory decision was supported by ATOMIC, a randomized phase 3 study that enrolled 712 patients with completely resected stage III dMMR colon cancer. Participants were assigned to modified FOLFOX6 chemotherapy alone or the same chemotherapy plus atezolizumab, with additional atezolizumab in the experimental group. Disease-free survival was the primary efficacy outcome.

At a median follow-up of about 37 months, adding atezolizumab reduced the hazard of disease recurrence or death by 50% compared with chemotherapy alone. Three-year disease-free survival was 86.4% with the atezolizumab strategy and 76.6% with chemotherapy alone. The absolute difference at three years was 9.8 percentage points.

The hazard ratio summarizes the relative event rate over follow-up; it does not mean every treated patient’s individual recurrence risk is halved. The randomized design supports a causal interpretation for the trial population and regimen, while the confidence interval indicates that the observed disease-free survival benefit was statistically compatible with a meaningful range of effect sizes.

Overall survival data were not mature enough to determine whether the disease-free survival improvement translates into longer life. Disease-free survival is clinically important in curative-intent colon cancer, but continued follow-up is needed to define the durability of benefit and any effect on survival after recurrence.

How biomarker status changes adjuvant selection

Before this approval, postoperative treatment selection for stage III colon cancer was driven principally by pathologic stage, recurrence risk, performance status, comorbidity and the suitability of an oxaliplatin-containing regimen. Mismatch-repair testing also informed hereditary cancer assessment and prognosis, but it did not establish an FDA-approved adjuvant checkpoint-inhibitor option for stage III disease.

The new indication makes the pathology result immediately relevant to treatment. For a patient with resected stage III disease, documentation of dMMR can support consideration of atezolizumab with chemotherapy. A mismatch-repair-proficient tumor does not meet the biomarker criterion, and the ATOMIC findings should not be extrapolated to that much larger group without evidence.

Testing should be available early enough to inform the postoperative discussion. If results are absent, equivocal or discordant—for example, if immunohistochemistry and microsatellite-instability testing do not align—review by pathology and, where appropriate, repeat or complementary testing may be needed before treatment selection. The approval does not make PD-L1 expression testing a prerequisite.

dMMR also has implications beyond drug eligibility. Loss patterns can suggest Lynch syndrome, although sporadic MLH1 loss is common and requires appropriate follow-up testing to distinguish it from a germline cause. Tumor biomarker testing and germline testing answer different questions; eligibility for adjuvant treatment should not be delayed by assuming that a dMMR result necessarily establishes an inherited syndrome.

For adolescents, the age threshold matters. The indication includes patients from age 12 onward, but pediatric representation in a predominantly adult colon cancer trial is expected to be limited because colon cancer is rare in children. Treatment planning should therefore account for the label, the available age-specific evidence and the expertise needed to manage chemotherapy and immune-related toxicity in younger patients.

Safety and remaining uncertainties

Adding atezolizumab increases treatment exposure and introduces the potential for immune-mediated adverse reactions affecting organs such as the lungs, liver, bowel, thyroid and other endocrine glands. These risks differ from the neuropathy, cytopenias, gastrointestinal effects and other toxicities associated with FOLFOX. The FDA labeling should guide patient selection, monitoring, treatment interruption and management; dosing or toxicity algorithms should not be inferred from the efficacy percentages alone.

Several limitations remain. The evidence comes from one biomarker-selected randomized trial, overall survival is immature, and follow-up is still relatively short for a potentially cured population. Evidence in adolescents is limited, while applicability to patients younger than 12 years, those with rectal cancer, stage II disease, incomplete resection or substantial contraindications to immunotherapy has not been established by this approval.

The trial also evaluated a defined sequence and duration of combination and maintenance treatment. Its results do not establish that atezolizumab alone can replace adjuvant chemotherapy, that other checkpoint inhibitors are interchangeable, or that treatment can be extended to mismatch-repair-proficient tumors. Longer follow-up will be important for late immune toxicity, recurrence patterns and overall survival.

Questions clinicians ask

Which patients now qualify for adjuvant atezolizumab?

The indication covers adults and pediatric patients aged 12 years or older with completely resected stage III colon cancer shown to be dMMR. It does not automatically apply to rectal cancer, metastatic disease, stage II colon cancer, children younger than 12 years or tumors with proficient mismatch repair.

Is microsatellite instability enough to establish eligibility?

MSI-high status often corresponds to dMMR, but the report and assay should be checked against the FDA labeling. Immunohistochemistry directly assesses mismatch-repair protein expression, while molecular MSI testing measures the genomic consequence; equivocal or discordant findings warrant pathology review rather than assumption.

Can atezolizumab replace postoperative chemotherapy?

No. The evidence supporting approval evaluated atezolizumab with modified FOLFOX6, followed by further atezolizumab, against chemotherapy alone. It did not test atezolizumab monotherapy as a substitute for standard adjuvant chemotherapy, so the observed benefit should be interpreted as evidence for the studied combined strategy.

Does every dMMR result require germline testing?

A dMMR result should prompt assessment for a possible inherited mismatch-repair disorder, but it does not by itself diagnose Lynch syndrome. The affected protein pattern, tumor testing for a sporadic cause, age, personal history and family history help determine whether genetic counseling and germline testing are appropriate.

References

1. FDA Approves Atezolizumab Plus Chemotherapy for Stage III Mismatch-Repair-Deficient Colon Cancer — US Food and Drug Administration, 2026 2. Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair — ClinicalTrials.gov, 2016